Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 2, keine Gesamtzahl für „Cibinqo“
Suchtreffer
Begriffe & Kennungen
Cibinqo · 4.5 · When abrocitinib 200 mg was administered concomitantly with probenecid, an OAT3 inhibitor, abrocitinib active
Eintrag öffnenCibinqo · 4.6 Fertility, pregnancy and lactation · 1
Eintrag öffnenCibinqo · 4.8 Undesirable effects · 1
Eintrag öffnenCibinqo · 4.8 · 11 Table 2. Adverse reactions System organ class Very common Common Uncommon Infections and infestations Herpe
Eintrag öffnenCibinqo · 4.8 · 12 Venous thromboembolism Among all patients treated in clinical studies with consistent dosing regimens of ei
Eintrag öffnenCibinqo · 4.8 · 13 Paediatric population
Eintrag öffnenCibinqo · 4.8 · A total of 3 850 patients were treated with abrocitinib in clinical studies in atopic dermatitis. Among them 3
Eintrag öffnenCibinqo · 4.8 · A total of 635 adolescent patients (12 to less than 18 years of age) were treated with abrocitinib in clinical
Eintrag öffnenCibinqo · 4.8 · Creatine phosphokinase elevations (CPK) In placebo-controlled studies, for up to 16 weeks, significant increas
Eintrag öffnenCibinqo · 4.8 · Description of selected adverse reactions
Eintrag öffnenCibinqo · 4.8 · In placebo-controlled studies, for up to 16 weeks, the rate of serious infections was 1.81 per 100 patient-yea
Eintrag öffnenCibinqo · 4.8 · Infections In placebo-controlled studies, for up to 16 weeks, infections have been reported in 27.4% of patien
Eintrag öffnenCibinqo · 4.8 · Lipid elevations In placebo-controlled studies, for up to 16 weeks, there was a dose-related increase in low-d
Eintrag öffnenCibinqo · 4.8 · Listed in Table 2 are adverse reactions observed in atopic dermatitis clinical studies presented by system org
Eintrag öffnenCibinqo · 4.8 · Lymphopenia In placebo-controlled studies, for up to 16 weeks, confirmed ALC < 0.5 × 103/mm3 occurred in 0.3%
Eintrag öffnenCibinqo · 4.8 · Nausea In placebo-controlled studies, for up to 16 weeks, nausea was reported in 1.8% of patients treated with
Eintrag öffnenCibinqo · 4.8 · Neutropenia Among all patients treated in clinical studies with consistent dosing regimens of either abrocitin
Eintrag öffnenCibinqo · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenCibinqo · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenCibinqo · 4.8 · Summary of the safety profile
Eintrag öffnen